Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administration of ZKLJ02 Injection in Healthy Chinese Research Participants

NCT07638098 is registered in ClinicalTrials.gov with Yunnan Zhongke Longjin Biotechnology Co.,Ltd. as lead sponsor.

NCT NCT07638098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administration of ZKLJ02 Injection in Healthy Chinese Research Participants
Lead sponsor
Yunnan Zhongke Longjin Biotechnology Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2025
Completion date
November 18, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

evaluate the safety and tolerability of zklj02 injection in healthy chinese research participants